Register Now

Already registered?
Access the webinar here »


You must have Javascript and Cookies enabled to access this webcast.

Webinar Summary

The advent of personalized medicine employing molecular targeted therapies has markedly changed the treatment of cancer in the past decade. Liquid biopsy is a rapidly emerging field to address this unmet clinical need as diagnostics based on cell-free circulating tumor DNA (ctDNA) can be a surrogate for the entire tumor genome.

We have developed a liquid biopsy technology “Electric Field Induced Release and Measurement (EFIRM)- Liquid Biopsy (eLB)” which provides the most accurate targeted detection that can assist clinical treatment decisions for the most common subtype of lung cancer, non-small cell lung cancer (NSCLC), where tyrosine kinase inhibitors (TKI) can extend the disease progress free survival period of these patients.

Attend this webinar to learn about:
  • The role of liquid biopsy in cancer detection
  • Electric field induced released and measurement (EFIRM), a novel liquid biopsy technology
  • The use and benefits of saliva as a sample type for liquid biopsy

Speaker Information:

David Wong
David Wong
Center for Oral/Head & Neck Oncology Research